Therapy of invasive fungal infections

Netherlands Journal of Medicine

Volumn 55, Issue 3, 1999, Pages 118-127

  Kullberg, Bart Jan ^a   De Pauw, Ben E ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antifungal therapy; Fungal infections; Invasive mycoses

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BONE MARROW SUPPRESSION; CANDIDIASIS; DRUG CHOICE; DRUG EFFICACY; FUNGAL MENINGITIS; GRANULOCYTE TRANSFUSION; HEPATITIS; HOST RESISTANCE; HUMAN; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMIC MYCOSIS;

EID: 0032795561     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(99)00022-4     Document Type: Article

References (59)

1. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, Hotchi M, Mall G, Martino P, Meunier F, Milliken S, Naoe S, Okudaira M, Scevola D, Van't Wout J. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992;11:99-109.
2. Como JA, Dismukes WE. Oral azole drugs as systemic antifungal therapy. New Engl J Med 1994;330:263-72.
3. Graybill JR, Vazquez J, Darouiche RO, Morhart R, Greenspan D, Tuazon C, Wheat LJ, Carey J, Leviton I, Hewitt RG, MacGregor RR, Valenti W, Restrepo M, Moskovitz BL. Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients. Am J Med 1998;104:33-9.
4. Powderly WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993;17:837-42.
5. Taelman H, Clerinx J, Kagame A, Batungwanayo J, Nyirabareja A, Bogaerts J. Cryptococcosis, another growing burden for central Africa. Lancet 1991;338:761.
6. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, Kaplowitz LG et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. New Engl J Med 1987;317:334-41.
7. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. New Engl J Med 1979;301:126-31.
8. Dismukes WE. Management of cryptococcosis. Clin Infect Dis 1993;17 (Suppl 2):S507-512.
9. Stern JJ, Hartman BJ, Sharkey P, Rowland V, Squires KE, Murray HW, Graybill JR. Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med 1988;85:477-80.
10. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301-8.
11. De Gans J, Portegies P, Tiessens G, Eeftinck Schattenkerk JK, van Boxtel CJ, van Ketel RJ, Stam J. Itraconazole compared with amphotericin B plus flucytosine in AIDS patients with cryptococcal meningitis. AIDS 1992;6:185-90.
12. Saag MS, Powderly WG, Cloud GA, Robinsin P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New Engl J Med 1992;326:83-9.
13. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Moskovitz BL, Powderly WG, Dismukes WE, National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. New Engl J Med 1997;337:15-21.
14. Bozette SA, Larsen RA, Chiu J, Leal MAE, Jacobsen J, Rothman P, Robinson P, Gilbert G, McCutchan JA, Tilles J, Leedom JM, Richman DD. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. New Engl J Med 1991;324:580-4.
15. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, Tuazon CU, Stern JJ, Feinberg J, Hafner R, Dismukes WE. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. New Engl J Med 1992;326:793-8.
16. Saag MS, Cloud GC, Graybill JR, Sobel J, Tuazon C, Wiesinger B, Riser L, Moskovitz BL, Dismukes WE, The NIAID Mycoses Study Group (MSG). In: Comparison of fluconazole versus itraconazole as maintenance therapy of AIDS-associated cryptococcal meningitis, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, Abstr. 1218, 1995.
17. Beck-Sagué CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
18. Voss A, Kluytmans JAJW, Koeleman JGM, Spanjaard L, Vandenbroucke-Grauls CMJE, Verbrugh HA, Vos MC, Weersink AYL, Hoogkamp-Korstanje JAA, Meis JFGM. Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitals. Eur J Clin Microb Infect Dis 1996;15:909-12.
19. Lecciones JA, Lee JW, Navarro EE, Witebsky FG, Marshall D, Steinberg SM, Pizzo PA, Walsh TJ. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis 1992;14:875-83.
20. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. New Engl J Med 1994;331:1325-30.
21. Viscoli C, Girmenia C, Marinus A, Collette L, Martino P, Lebau B, Spence D, Kremery V, De Pauw BE, Meunier F, The Invasive Fungal Infection Group of the European Organization for Research and Treatment of Cancer. Candidemia in cancer patients. Results of a prospective, mul ticenter surveillance study in Europe. Clin Infect Dis 1999; in press.
22. Wingard JR, Dick JD, Merz WG, Sandford GR, Saral R, Burns WH. Pathogenicity of Candida tropicalis and Candida albicans after gastrointestinal inoculation in mice. Infect Immun 1980;29:808-13.
23. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD for the NIAID Study Group and the Candidemia Study Group. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 1995;39:40-4.
24. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20:115-25.
25. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry AL, Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of interpretive break-points for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Clin Infect Dis 1997;24:235-47.
26. Komshian SV, Uwaydah AK, Sobel JD, Crane LR. Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis 1989;11:379-90.
27. Beutler SM, Young LS, Lindquist LA, Montgomerie JZ, Edwards Jr. JE. Delayed complications of candidemia. In: Program and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, FL, 1982, p. 154.
28. Edwards Jr. JE. Should all patients with candidemia be treated with antifungal agents? Clin Infect Dis 1992;15:422-3.
29. Van't Wout JW, Mattie H, Van Furth R. A prospective study of the efficacy of fluconazole (UK 49,858) against deep-seated fungal infections. Antimicrob Agents Chemother 1988;31:665-72.
30. Nguyen MH, Peacock Jr. JE, Tanner DC, Morris AJ, Nguyen nydma ML, Snydman DR, Wagener MM, Yu VL. Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch Intern Med 1995;155:2429-35.
31. Anaissie EJ, Vartivarian SE, Abi-Said D, Uzun O, Pinczowski H, Kontoyiannis DP, Khoury P, Papadakis K, Gardner A, Raad II, Gilbreath J, Bodey GP. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med 1996;101:170-6.
32. Anaissie EJ, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP. Management of invasive candidal infections: Results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996;23:974-2.
33. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997;16:51-5.
34. Oude Lashof AML, Donnelly JP, Meis JFGM, Van der Meer JWM, Kullberg BJ. Duration of antifungal treatment and development of delayed complications in patients with candidemia. In: 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstr. J97. San Diego, CA, 1998, p. 478.
35. Martino P, Girmenia C, Micozzi A, De Bernardis F, Boccanera M, Cassone A. Prospective study of Candida colonization, use of empiric amphotericin B and development of invasive mycosis in neutropenic patients. Eur J Clin Microbiol Infect Dis 1994;13:797-804.
36. Pittet D, Monod M, Suter PM, Frenk E, Auckenthaler R. Candida colonization and subsequent infections in critically ill surgical patients. Ann Surg 1994;220:751-8.
37. Eppes SC, Troutman JL, Gutman LT. Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 1989;8:99-104.
38. Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE, Washburn RG, for the NIAID Mycoses Study Group and the Candidemia Study Group. Intravascular catheter exchange and duration of candidemia. Clin Infect Dis 1995;21:994-6.
39. Guiot HFL, Fibbe WE, Van't Wout JW. Risk factors for fungal infection in patients with malignant hematologic disorders - implications for empirical therapy and prophylaxis. Clin Infect Dis 1994;18:525-32.
40. Kullberg BJ, Vandewoude K, Herbrecht R, Jacobs F, Aoun M, Kujath P. A double-blind, randomized, placebo-controlled Phase II study of filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients. In: 38th Interscience Conference on Anti-microbial Agents and Chemotherapy, Abstr. J100, San Diego, CA, 1998, p. 479.
41. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996;23:608-15.
42. Verweij PE, Donnelly JP, Kullberg BJ, Meis JFGM, De Pauw BE. Amphotericin B versus amphotericin B plus 5-flucytosine: poor results in the treatment of proven systemic mycoses in neutropenic patients. Infection 1994;22:81-5.
43. Van't Wout JW, Novakova I, Verhagen CAH, Fibbe WE, De Pauw BE, Van der Meer JWM. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991;22:45-52.
44. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997;157:1857-62.
45. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997;15:139-47.
46. Drutz DJ. Rapid infusion of amphotericin B: is it safe, effective, and wise? Am J Med 1992;93:119-21.
47. Ellis ME, Al-Hokail AA, Clink HM, Padmos MA, Ernst P, Spence DG, Tharpe WN, Hillier VF. Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B. Antimicrob Agents Chemother 1992;36:172-9.
48. Cruz JM, Peacock Jr. JE, Loomer L, Holder LW, Evans GW, Powell BL, Lyerly ES, Capizzi RL. Rapid intravenous infusion of amphotericin B: a pilot study. Am J Med 1992;93:123-30.
49. Khoo SH, Bond J, Denning DW. Administering amphotericin B - a practical approach. J Antimicrob Chemother 1994;33:203-13.
50. Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med 1983;75:476-81.
51. Branch RA. Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch Intern Med 1988;148:2389-94.
52. Walsh TJ, Bodensteiner D, Hiemenz J, Thaler S, Greenberg R, Arndt C, Holgenberg J, Schwartz C, Pappas P, Dummer S, Marsh R, Schuster M, Seibel N, the empirical antifungal study group and the mycoses study group. A randomized, double-blind trial of AmBisome (liposomal amphotericin B) versus amphotericin B in the empirical treatment of persistently febrile neutropenic patients. In: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario, Abstr. LM-90, 1997, p. 381.
53. Ellis M, Spence D, De Pauw BE, Meunier F, Marinus A, Collette L, Sylvester R, Meis JFGM, Bogaerts M, Selleslag D, Krcmery V, Von Sinner W, MacDonald P, Doyen C, Vandercam B. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-12.
54. Moreau P, Milpied N, Fayette N, Ramee JF, Harousseau JL. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother 1992;30:535-41.
55. Schöffski P, Freund M, Wunder R, Petersen D, Kohne CH, Hecker H, Schubert U, Ganser A. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. Br Med J 1998;317:379-84.
56. Joly V, Aubry P, Ndayiragide A, Carriere I, Kawa E, Mlika-Cabanne N, Aboulker JP, Coulaud JP, Larouze B, Yeni P. Randomized comparison of amphotericin B deoxycholate dissolved in dextrose or Intralipid for the treatment of AIDS-associated cryptococcal meningitis. Clin Infect Dis 1996;23:556-62.
57. Trissel LA. Amphotericin B does not mix with fat emulsion. Am J Health Syst Pharm 1995;52:1463-4.
58. Kullberg BJ, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. Res Immunol 1998;149:478-88.
59. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Andersson BS, Freireich EJ. Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study. Leukemia 1997;11:1621-30.